Oncotype DX AR-V7 Nucleus Detect

Frequently Asked Questions

What is the AR-V7 Nucleus Detect test?

The Oncotype DX AR-V7 Nucleus Detect test is a test performed through a simple blood draw. It tests whether your tumor will respond to androgen receptor (AR)-targeted therapies, such as XTANDI® or ZYTIGA®*. With the results of this test, your doctor can more confidently recommend whether AR-targeted therapy or chemotherapy is right for you.

Who is Eligible?

The Oncotype DX AR-V7 Nucleus Detect test is an option if you have metastatic castration-resistant prostate cancer (mCRPC) and your doctor is considering androgen receptor (AR)-targeted therapies, such as XTANDI® or ZYTIGA®, for your treatment. Since most mCRPC patients become resistant to AR-targeted therapies over time, the test may be performed several times during the course of your treatment.

Am I eligible if I have already had treatment with XTANDI® or ZYTIGA®?

Yes. Patients with metastatic castration-resistant prostate cancer (mCRPC) are often given several rounds of androgen receptor (AR)-targeted therapies, such as XTANDI or ZYTIGA. Because the Oncotype DX AR-V7 Nucleus Detect test detects whether your tumor has become resistant to AR-targeted therapies, AR-V7 Nucleus Detect may be performed between each round of therapy.

What causes resistance to XTANDI® or ZYTIGA®?

Tumors can adapt (and become resistant) to androgen receptor (AR)-targeted therapies, such as XTANDI or ZYTIGA, develop AR-targeted treatments. In fact, most patients who initially respond to (AR)-targeted therapies develop acquired resistance to them over time.

What kind of treatment will I get if I am resistant to XTANDI® or ZYTIGA®?

Patients with metastatic castration-resistant prostate cancer (mCRPC) tumors that are resistant to androgen receptor-targeted therapies, such as XTANDI or ZYTIGA, are often given taxane chemotherapy. Chemotherapy can both reduce cancer-related symptoms and improve survival. Doctors give chemotherapy in cycles, with each period of treatment followed by a rest period to allow the body time to recover. Each cycle typically lasts for a few weeks.

How long will it take to get the test results of the Oncotype DX test?

Most results from the Oncotype DX AR-V7 Nucleus Detect test are available within two weeks from the date your blood sample is received by the our laboratory. The results are sent to your doctor so that he or she can discuss the results with you and answer your questions.

Is the Oncotype DX test covered by insurance?

Since insurance coverage can vary across the country, it’s a good idea to check with your insurance carrier to confirm the test is covered by your insurance.

*Xtandi® is a registered trademark of Astellas Pharma, Inc. Zytiga® is a registered trademark of Johnson and Johnson.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™